Chairman & CEO, Eisai Inc. Global Alzheimer’s Disease Officer & Senior Corporate Officer, Eisai Co., Ltd.
Ivan Cheung concurrently serves as Chairman and CEO of Eisai Inc. in the United States, as well as Global Alzheimer’s Disease Officer and Senior Corporate Officer for Eisai Co., Ltd. in Japan, the parent company of Eisai Inc. He is responsible for
Ivan Cheung concurrently serves as Chairman and CEO of Eisai Inc. in the United States, as well as Global Alzheimer’s Disease Officer and Senior Corporate Officer for Eisai Co., Ltd. in Japan, the parent company of Eisai Inc. He is responsible for the strategic direction of the company in North America, which is the largest commercial region for Eisai globally. Mr. Cheung provides management oversight to all of Eisai's operating companies in the United States and Canada, including fully integrated commercial and medical organizations specializing in oncology and neurology, as well as multiple research and development facilities. He is also responsible for Eisai’s global end-to-end strategy and activities from new product development and regulatory affairs to brand commercialization and value/access to deliver breakthrough disease-modifying therapies and ecosystem solutions to people living with Alzheimer’s disease and related brain health conditions.
Since joining Eisai Co., Ltd. in 2005, Ivan has held positions of rising responsibility across corporate planning and strategy, corporate finance, talent management, global R&D, the U.S. pharmaceuticals business, the Japan consumer healthcare business, the global oncology business, and the global neurology business. Prior to joining Eisai, he was with the Global Health Practice at Booz Allen Hamilton, where he provided strategy and operations consulting to biopharmaceutical and healthcare clients in the U.S., Europe, and Asia.
Ivan received his MBA from Harvard Business School, and earned a Bachelor of Science degree in Civil/Environmental Engineering with a double major in Economics from Duke University. He is a Board member of the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO).